

Hepatitis C Caring Ambassadors Program Newsletter

November 2006

IN THE NEWS

HIV/Hep C Cases Rising in Sudbury

<http://www.northernlife.ca/News/Lifestyle/2006/12-01-06-aidsTOP.asp?NLStory=12-01-06-aidsTOP>

“Ecole Secondaire Macdonald-Cartier student Alex Vincent looked a little embarrassed when he was asked what he knows about HIV/AIDS or other sexually transmitted diseases.”

China's Hepatitis C Prevalent Population is Ten Times that of the United States

<http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-05-2006/0004485476&EDATE=>

“Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, estimates that China's hepatitis C virus (HCV) prevalent population is ten times that of the United States.”

SAARC Nations Unprepared for Liver Disease Epidemic

http://www.thenews.com.pk/daily_detail.asp?id=34419

“KARACHI: The people of South Asia, especially Pakistan, are unprepared for an epidemic of deadly liver diseases as there is not even a single liver transplantation centre in the country, warn medical experts.”

Closing Prison Tattoo Parlours Can Only Cause Infectious Diseases to Spread Beyond Jails, Warns *Leon Mar*

http://www.thestar.com/NASApp/cs/ContentServer?pagename=thestar/Layout/Article_Type1&c=Article&cid=1164922265416&call_pageid=970599119419

“Public Safety Minister Stockwell Day is facing a crucial and controversial decision on prison tattoo parlours that could reduce the rate of infectious diseases (like HIV and hepatitis C) not only among prisoners, but among the public at large. Evidence and experts suggest his choice is clear: Safer tattooing programs save money and lives and should be implemented in all prisons in Canada. But political decisions are rarely based on evidence alone.”

Licensing deal coup: DRUG maker Biota will boost the size of its research team after signing a \$102 million licensing deal yesterday for a possible treatment for hepatitis C.

<http://www.news.com.au/couriermail/story/0,23739,20833516-3122,00.html>

“German pharmaceutical giant Boehringer Ingelheim bought into the early-stage drug deal knowing that it will reap huge rewards should it get a breakthrough treatment for the virus. Hepatitis C has infected 4.1 million Americans where between 1-5 per cent of sufferers die from the complaint, according to figures produced by the US Centre for Disease Control.”

Arrow Therapeutics HCV Compound Enters Phase I

http://www.earthtimes.org/articles/show/news_press_release,26236.shtml

“Arrow Therapeutics, the London based antiviral drug discovery and development company, has announced that it has initiated a Phase I study of A-831, a small molecule antiviral inhibitor of Hepatitis C infection. The study will evaluate the safety, tolerability and pharmacokinetics of single escalating doses of A-831 in healthy volunteers in the UK.”

Egypt Launches 5-Year National Campaign Against HIV/AIDS, Hepatitis C Among Children

http://english.people.com.cn/200611/24/eng20061124_324692.html

“Egypt Thursday launched a five-year campaign to help the Egyptian children fight against the HIV/AIDS and Hepatitis C diseases. Under the theme of uniting for children against AIDS and hepatitis C, the campaign was

cosponsored by the Egyptian Ministry of Health and Population, the United Nations International Children's Emergency Fund (UNICEF) and U.S. Coca-Cola North and West Africa.”

Bayer Diagnostics and Innogenetics launch Versant HCV Genotype 2.0 assay (LiPA) for HCV genotyping
<http://www.medadnews.com/News/Index.cfm?articleid=393787>

“November 21, 2006 –Bayer HealthCare, Diagnostics Division, a member of the Bayer Group and Innogenetics N.V. announced today that the VERSANT® HCV (Hepatitis C Virus) Genotype 2.0 Assay (LiPA) has been released for sale in Europe. This next generation hepatitis C assay is an upgrade of Bayer’s VERSANT® HCV Genotype 1.0 Assay (LiPA), which is considered to be the most widely used assay for HCV Genotyping.”

Thousands Unknowingly Infected with Hepatitis C
<http://www.ksl.com/index.php?nid=148&sid=646083>

“Fifty to sixty thousand people in Utah have an infection and most - probably 90 percent - don't even know they have it. While many were infected as long as 30 years ago symptoms are just now showing up. It's like reading an insidious mystery. Imagine trying to read that mystery. You check out the book only to find the pages at the end are missing. You never find out when it happened or who did it!”

Drug in New Hepatitis C Clinical Trial
<http://biz.yahoo.com/prnews/061114/sftu184.html?.v=2>

“BRISBANE, Australia, -- Physicians at Brisbane's Princess Alexandra Hospital have treated the first two patients in a clinical trial designed to test a new strategy for defeating hepatitis C viral infection, one of the toughest infectious diseases in the modern world.”

Prisons make unhealthy cuts on hepatitis testing
<http://www.freep.com/apps/pbcs.dll/article?AID=/20061113/OPINION01/611130305/1068/opinion>

“Depending whether you believe the state or outside experts, Michigan prisons hold 7,000 to 18,000 inmates infected with hepatitis C. That's 14-40% -- and most of them don't even know they have the disease.”

Vertex May Beat Roche, Merck on Drug for Hepatitis C
<http://www.bloomberg.com/apps/news?pid=20601109&sid=a1XXDRUwcAfE&refer=home>

“Vertex Pharmaceuticals Inc., a biotechnology company founded in 1989, may beat drugmakers from Roche Holding AG to Merck & Co. to produce the first medicine in a decade to treat hepatitis C, the main cause of liver cancer. Vertex's drug, which the company plans to seek approval for in 2008, is one of several treatments in patient testing.”

Patients Who Recover From Hepatitis C Have Lower Risk of Reinfection
<http://www.docguide.com/news/content.nsf/news/852571020057CCF68525721A004CB12D>

“A new study found that individuals who had tested positive for hepatitis C (HCV) but later tested negative for the virus were significantly less likely to become infected again compared to those who had never been infected, even though they had the same exposure risks.”

Students at Unusual Risk of Contracting Hepatitis C, study says
<http://www.statehonet.com/vnews/display.v/ART/2006/11/03/454b61b6319f1>

“The next time you consider getting a tattoo or borrowing a roommate's toothbrush, you may want to think twice. Such behaviors put college students at risk for contracting Hepatitis C, according to a new study from Eastern Michigan University. The study also shows that students are unaware that many of their behaviors put them at especially high risk of contracting Hepatitis C, a disease of the liver that has no cure and can lead to chronic liver disease, cirrhosis and death.”

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Everson GT, et al. *Hepatology*. 2006 Dec;44(6):1675-84.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17133499&query_hl=8&itool=pubmed_DocSum

Relationship between the severity of hepatitis C virus-related liver disease and the presence of *Helicobacter* species in the liver: A prospective study. Castera L, et al. *World J Gastroenterol*. 2006 Dec 7;12(45):7278-84.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17143941&query_hl=8&itool=pubmed_docsum

Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C. Gatselis NK, et al. *Aliment Pharmacol Ther*. 2006 Nov 10; [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17094775&query_hl=8&itool=pubmed_DocSum

Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy. Medeiros-Filho JE, et al. *World J Gastroenterol*. 2006 Dec 7;12(45):7271-7.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17143940&query_hl=8&itool=pubmed_docsum

The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Sanyal AJ, et al. *Gastrointest Endosc*. 2006 Dec;64(6):855-864.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17140886&query_hl=8&itool=pubmed_docsum

Heterozygous {beta} -globin gene mutations as a risk factor for iron accumulation and liver fibrosis in chronic hepatitis c. Sartori M, et al. *Gut*. 2006 Nov 29 [Epub ahead of print].
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17135308&query_hl=8&itool=pubmed_DocSum

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Mazzaferro V, et al. *Hepatology*. 2006 Dec;44(6):1543-54.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17133492&query_hl=8&itool=pubmed_DocSum

Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Bugianesi E, et al. *Hepatology*. 2006 Dec;44(6):1648-55.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17133473&query_hl=8&itool=pubmed_DocSum

Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Snoeck E, et al. *Br J Clin Pharmacol*. 2006 Dec;62(6):699-709.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17118125&query_hl=8&itool=pubmed_DocSum

Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b. Abergel A, et al. *J Viral Hepat*. 2006 Dec;13(12):811-20.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17109680&query_hl=8&itool=pubmed_DocSum

Hepatitis C virus transmission and its risk factors within families of patients infected with hepatitis C virus in southern Iran: Khuzestan. Hajiani E, et al. World J Gastroenterol. 2006 Nov 21;12(43):7025-8.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17109499&query_hl=8&itool=pubmed_DocSum

Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: A randomized controlled trial. Alaimo G, et al. World J Gastroenterol. 2006 Nov 14;12(42):6861-4.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17106937&query_hl=8&itool=pubmed_DocSum

Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C. Yoshiji H, et al. World J Gastroenterol. 2006 Nov 14;12(42):6786-91.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17106926&query_hl=8&itool=pubmed_DocSum

A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. Yu ML, et al. Liver Int. 2006 Dec;26(10):1187-95.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17105583&query_hl=8&itool=pubmed_DocSum

Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV. Deterding K, et al. J Hepatol. 2006 Dec;45(6):770-8. Epub 2006 Sep 22.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17034895&query_hl=8&itool=pubmed_DocSum

Direct and indirect evidence for the reversibility of cirrhosis. Serpaggi J, et al. Hum Pathol. 2006 Dec;37(12):1519-26. Epub 2006 Sep 25.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16997354&query_hl=8&itool=pubmed_DocSum

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

Serendipitous identification of natural intergenotypic recombinants of hepatitis C in Ireland. Moreau I, et al. Virol J. 2006 Nov 15;3:95.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17107614&query_hl=8&itool=pubmed_DocSum

Small interfering RNA targeted to stem-loop II of the 5 untranslated region effectively inhibits expression of six HCV genotypes. Prabhu R, et al. Virol J. 2006 Nov 27;3(1):100 [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17129382&query_hl=8&itool=pubmed_DocSum

Hepatitis C virus genotype 1b chimeric replicon containing genotype 3 NS5A domain. Lanford RE, et al. Virology. 2006 Nov 25;355(2):192-202. Epub 2006 Aug 21.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16919701&query_hl=8&itool=pubmed_DocSum

Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. Capone S, et al. J Immunol. 2006 Nov 15;177(10):7462-71.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17082666&query_hl=8&itool=pubmed_DocSum

Hepatitis C Virus (HCV) Core Protein-Induced, Monocyte-Mediated Mechanisms of Reduced IFN- α and Plasmacytoid Dendritic Cell Loss in Chronic HCV Infection. Dolganiuc A, et al. J Immunol. 2006 Nov 15;177(10):6758-68.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17082589&query_hl=8&itool=pubmed_DocSum

Equal amounts of intracellular and virion-enclosed hepatitis C virus RNA are associated with peripheral-blood mononuclear cells in vivo. Kaiser P, et al. J Infect Dis. 2006 Dec 15;194(12):1713-23. Epub 2006 Nov 13.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17109344&query_hl=8&itool=pubmed_DocSum

Discovery of Conformationally Constrained Tetracyclic Compounds as Potent Hepatitis C Virus NS5B RNA Polymerase Inhibitors. Ikegashira K, et al. J Med Chem. 2006 Nov 30;49(24):6950-6953.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17125247&query_hl=8&itool=pubmed_DocSum

Distinct cellular responses differentiating alcohol- and hepatitis C virus-induced liver cirrhosis. Lederer SL, et al. Virol J. 2006 Nov 22;3:98.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17121680&query_hl=8&itool=pubmed_DocSum

Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models. Li YP, et al. World J Gastroenterol. 2006 Nov 28;12(44):7126-35.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17131474&query_hl=8&itool=pubmed_DocSum

Genetic vaccination with Flt3-L and GM-CSF as adjuvants: Enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis C virus infection. Encke J, et al. World J Gastroenterol. 2006 Nov 28;12(44):7118-25.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17131473&query_hl=8&itool=pubmed_DocSum

The protein kinase IKKepsilon can inhibit HCV expression independently of IFN and its own expression is downregulated in HCV-infected livers. Vilasco M, et al. Hepatology. 2006 Dec;44(6):1635-47.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17133498&query_hl=8&itool=pubmed_DocSum

In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease. Liu R, et al. J Antimicrob Chemother. 2006 Dec 5; [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17151003&query_hl=8&itool=pubmed_docsum

Modulation of the IL-12/IFN- γ axis by IFN- α therapy for hepatitis C. Byrnes AA, et al. J Leukoc Biol. 2006 Dec 5; [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17148690&query_hl=8&itool=pubmed_docsum

Involvement of PA28 γ -Dependent Pathway in Insulin Resistance Induced by Hepatitis C Virus Core Protein. Miyamoto H, et al. J Virol. 2006 Nov 29; [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17135326&query_hl=8&itool=pubmed_docsum

HIV/HCV COINFECTION

Hepatitis C virus and non-Hodgkin's lymphoma: findings from the Swiss HIV Cohort Study. Franceschi S, et al. *Br J Cancer*. 2006 Dec 4;95(11):1598-602. Epub 2006 Nov 14.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17106439&query_hl=8&itool=pubmed_DocSum

Negative-Strand Hepatitis C Virus (HCV) RNA in Peripheral Blood Mononuclear Cells from Anti-HCV-Positive/HIV-Infected Women. Laskus T, et al. *J Infect Dis*. 2007 Jan 1;195(1):124-133. Epub 2006 Nov 27.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17152016&query_hl=8&itool=pubmed_docsum

Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfecting with HIV and hepatitis C virus. Backus LI, et al. *J Viral Hepat*. 2006 Dec;13(12):799-810.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17109679&query_hl=8&itool=pubmed_DocSum

Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. Mehta SH, et al. *AIDS*. 2006 Nov 28;20(18):2361-9.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17117023&query_hl=8&itool=pubmed_DocSum

Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002.

Martin-Carbonero L, et al. *J Viral Hepat*. 2006 Dec;13(12):851-7.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17109686&query_hl=8&itool=pubmed_DocSum

MISCELLANEOUS

Occult hepatitis C virus infection: A new form of hepatitis C. Carreno V. *World J Gastroenterol*. 2006 Nov 21;12(43):6922-5.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17109511&query_hl=8&itool=pubmed_DocSum

A single alcohol ingestion does not affect serum hepatitis C virus RNA in patients with chronic hepatitis C.

Manolakopoulos S, et al. *Liver Int*. 2006 Dec;26(10):1196-200.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17105584&query_hl=8&itool=pubmed_DocSum

The hepatitis C virus epidemic in Cameroon: Genetic evidence for rapid transmission between 1920 and 1960. Njouom R, et al. *Infect Genet Evol*. 2006 Nov 28; [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17137845&query_hl=8&itool=pubmed_docsum

Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Del Rio RA, et al. *Hepatology*. 2006 Dec;44(6):1598-606.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17133490&query_hl=8&itool=pubmed_DocSum

Hepatitis C in people with mental illness: how big is the problem and how do we respond? Seccull A, et al.

Australas Psychiatry. 2006 Dec;14(4):374-8.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17116075&query_hl=8&itool=pubmed_DocSum

Impaired health-related quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levels. von Wagner M, et al. *J Viral Hepat*. 2006 Dec;13(12):828-34.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17109682&query_hl=8&itool=pubmed_DocSum

Follow-up for medical care among drug users with hepatitis C. Reynolds GL, et al. Eval Health Prof. 2006 Dec;29(4):355-66.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17102060&query_hl=8&itool=pubmed_DocSum

Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naive Chinese patients with chronic hepatitis C. Lin WA, et al. Aliment Pharmacol Ther. 2006 Nov 15;24(10):1483-93.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17081165&query_hl=8&itool=pubmed_DocSum

Combined Hepatitis C Virus (HCV) Antigen-Antibody Detection Assay Does Not Improve Diagnosis for Seronegative Individuals with Occult HCV Infection. Quiroga JA, et al. J Clin Microbiol. 2006 Dec;44(12):4559-4560. Epub 2006 Oct 4.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17021056&query_hl=8&itool=pubmed_DocSum

Illness-related stigma, mood and adjustment to illness in persons with hepatitis C. Golden J, et al. Soc Sci Med. 2006 Dec;63(12):3188-98. Epub 2006 Sep 28.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17010490&query_hl=8&itool=pubmed_DocSum